We are advised by Arkbio that journalists and other readers should disregard the news release, Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD, issued on Jan. 6, 2026 by Arkbio over PR Newswire, as the release contained inappropriate information.
source: Arkbio
【你點睇？】香港IPO監管趨嚴收緊，你認為會否影響香港新股市場吸引力？你認為嚴格審批是否有助提升上市公司質素？► 立即投票
